Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03173287
Other study ID # CHU-327
Secondary ID 2016-A02066-45
Status Recruiting
Phase N/A
First received May 9, 2017
Last updated May 31, 2017
Start date March 1, 2017
Est. completion date November 2018

Study information

Verified date May 2017
Source University Hospital, Clermont-Ferrand
Contact Patrick LACARIN
Phone 04 73 75 11 95
Email placarin@chu-clermontferrand.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Quantification of hepatic fibrosis by IVIM sequences in 1.5T MRI.


Description:

Early and accurate diagnosis of hepatic fibrosis in patients with chronic liver disease is essential and essential. This assessment could be performed by a non-invasive MRI method.

The main objective of this study is to show that the measured perfusion-related scattering value (D *) is related to the hepatic fibrosis stage.

Secondary objectives

- Evaluation of infusion fraction (f) and fibrosis stage.

- Evaluation of molecular diffusion (D) and fibrosis stage.

- Evaluation of ADC and fibrosis stage.

- Assess whether there is a link between the etiology of fibrosis and the value of the diffusion.


Recruitment information / eligibility

Status Recruiting
Enrollment 63
Est. completion date November 2018
Est. primary completion date March 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria:

- Patients undergoing hepatic biopsy (trans-parietal or trans-jugular) in the context of liver disease

- Signature of written consent

Exclusion Criteria:

- Contra-indications to MRI

- Refusal of protocol

- Underage patients and protected adults

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Quantification of liver fibrosis
Procedure MRI and liver biopsy

Locations

Country Name City State
France CHU de Clermont-Ferrand Clermont-Ferrand Auvergne

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measured perfusion-related scattering value The main objective of this study is to show that the measured perfusion-related scattering value (D *) is related to the hepatic fibrosis stage. at day 1
Secondary Measured perfusion-related of infusion fraction at day 1
Secondary Measured perfusion-related of molecular diffusion at day 1
Secondary Measured perfusion-related of ADC at day 1
See also
  Status Clinical Trial Phase
Recruiting NCT06308757 - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis N/A
Recruiting NCT06051669 - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Recruiting NCT06098417 - Biomarkers in the Diagnosis and Prognosis of NAFLD
Not yet recruiting NCT03623360 - Functional MRI to Determine Severity of Cirrhosis
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Not yet recruiting NCT01133184 - Improved Prevention of Perinatal Hepatitis B Transmission Phase 4
Completed NCT00043303 - Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis Phase 2
Completed NCT03872024 - Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients N/A
Recruiting NCT05912179 - Prospective Single Centre Observational Study to Compare the Diagnostic Yield of Different Modalities of Liver Biopsy
Recruiting NCT04533828 - 68Ga-FAPI PET/CT in Liver Fibrosis Patients Early Phase 1
Completed NCT04573543 - The Role of Immune Semaphorins in NAFLD
Recruiting NCT03277651 - Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension N/A
Completed NCT01707472 - Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis Phase 2
Completed NCT01988753 - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Completed NCT02060162 - Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
Completed NCT01810458 - Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3
Completed NCT00049842 - Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED) Phase 3
Recruiting NCT06063785 - Multispectral Optoacoustic Tomography in Patients With Cystic Fibrosis